NCT01123876已完成1 期
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)8 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2010年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 8
- 主要终点
- Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors
研究概览
简要总结
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be at least 18 years of age.
- •Subjects in the dose escalation cohorts must have: * Subjects with histologically or cytologically confirmed malignancy that is meta static or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective or for whom treatment with FOLFIRI is a viable option.
- •Subjects in the expanded safety cohort must have: * Histological confirmed advanced colorectal cancer.
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0 to
- •Subject must have adequate hematologic, renal and hepatic function as follows: * Bone Marrow: Absolute neutrophil count ANC >= 1,500/mm3; Platelets >= 100,000/mm3; Hemoglobin >= 9.5 g/dL; * Renal function: Serum creatinine < 1.5 * upper normal limit of institution's normal range OR creatinine clearance <= 50 mL/min/1.73m2 for subjects with creatinine levels above institutional normal; * Hepatic function: AST and ALT <= 2.5 * the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT <= 5 * the upper normal limit of institution's normal range; * Bilirubin <= 1.5 * the upper normal limit of institution's normal range;
- •Partial Thromboplastin Time (PTT) must be <= 1.5 * the upper normal limit of institution's normal range and INR < 1.
- •Subjects on anticoagulant (such as Coumadin) will have PTT and INR as determined by the investigator.
- •Women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for 90 days following completion of therapy. Women of childbearing potential must have a negative serum pregnancy test within 21 days prior to initiation of treatment and/or post menopausal women must be amenorrheic for at least 12 months to be considered of non childbearing potential. * Total abstinence from sexual intercourse (minimum one complete menstrual cycle); * Vasectomized partner of female subjects; * Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; * Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream); * IUD (Intra-Uterine Device); * Additionally, male subjects (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completions of therapy.
- •Subject is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
- •The subject has received up to 3 prior DNA damaging agents or cytotoxic chemotherapy treatments (prior therapies with biologic agents including, IL -2, interferon, vaccines, immunostimulants and signal transduction inhibitors are allowed) Chemotherapy received as adjuvant therapy before 2 years will not be considered as prior chemotherapy.
排除标准
- •Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within 28 days prior to study drug administration. Subjects receiving hormone therapy, bisphosphonates or LHRH-agonists are eligible. Subjects who have not recovered to within one grade level (not to exceed Grade 2) of their baseline following a significant adverse event or toxicity attributed to previously anti-cancer treatment are excluded.
- •Subjects in the expanded safety cohorts only, have previously been treated with a PARP inhibitor.
- •Subjects with a known history of brain metastases and primary CNS tumors
- •Subjects with a known hypersensitivity to CPT11, 5-FU or Folinic Acid.
- •Clinically significant and uncontrolled major medical condition(s) including but not limited to: * Uncontrolled nausea/vomiting/diarrhea; * Active uncontrolled infection; * Symptomatic congestive heart failure; * Unstable angina pectoris or cardiac arrhythmia; * Psychiatric illness/social situation that would limit compliance with study requirements. * Gilbert's Syndrome * Any medical condition, which in the opinion of the study investigator, places the patient at an unacceptably high risk for toxicities
- •Subjects that are being treated with Ketoconazole, enzyme-inducing anticonvulsants, and or St. John's Wort.
- •Subject is pregnant or lactating.
- •Subject who requires parenteral nutrition, tube feeding or has evidence of partial bowel obstruction or perforation within 28 days prior to study drug administration.
- •The subject has had another active malignancy within the past 3 years except for any cancer in situ that the Principal Investigator considers to be cured.
- •Previous exposure to Irinotecan.
研究组 & 干预措施
Veliparib and FOLFIRI
Experimental
Veliparib in combination with FOLFIRI regimen.
干预措施: Veliparib (Drug)
结局指标
主要结局
Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors
时间窗: Screening to follow up visit
次要结局
- To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens.(Screening to follow up visit)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2AAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAdult Pure Erythroid LeukemiaChronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 PositiveDe Novo Myelodysplastic SyndromeHematopoietic and Lymphoid Cell NeoplasmRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaPolycythemia VeraEssential ThrombocythemiaMyelodysplastic SyndromeNCT00588991National Cancer Institute (NCI)12
进行中（未招募）
1 期
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionBreast CarcinomaCarcinoma of Unknown PrimaryEndometrial CarcinomaLung CarcinomaMalignant Head and Neck NeoplasmMalignant Testicular NeoplasmMetastatic Malignant Solid NeoplasmOvarian CarcinomaUnresectable Malignant NeoplasmLiver FailureMelanomaEsophageal CarcinomaRenal FailureUrothelial CarcinomaNCT01366144National Cancer Institute (NCI)94
进行中（未招募）
1 期
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerRecurrent Breast CarcinomaStage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast CarcinomaNCT01251874National Cancer Institute (NCI)44
已完成
1 期
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsAdult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeMale Breast CarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerTriple-Negative Breast CarcinomaNCT01281150National Cancer Institute (NCI)22
已完成
1 期
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid CancerAdult Solid NeoplasmBRCA1 Mutation CarrierBRCA2 Mutation CarrierHereditary Breast and Ovarian Cancer SyndromeNCT00535119National Cancer Institute (NCI)107